NCT02530619View on ClinicalTrials.gov

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

NAUnknownINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 9, 2015

Primary Completion Date

May 21, 2018

Study Completion Date

May 31, 2022

Conditions
Acute Megakaryoblastic LeukemiaMyelofibrosisPrimary Myelofibrosis
Interventions
DRUG

Alisertib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (3)

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

55905

Mayo Clinic, Rochester

60611

Northwestern University, Chicago

Sponsors
All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER